ICON PLC Files 6-K for Q1 2024
Ticker: ICLR · Form: 6-K · Filed: Apr 25, 2024 · CIK: 1060955
Sentiment: neutral
Topics: financial-reporting, 6-K, quarterly-update
TL;DR
ICON PLC's Q1 2024 6-K is out, showing financial details and key balance sheet items as of March 31, 2024.
AI Summary
ICON PLC filed a 6-K report for the period ending March 31, 2024. The filing includes financial data and disclosures for the first quarter of 2024. Key financial information such as common stock, additional paid-in capital, and retained earnings as of December 31, 2023, are detailed. The company's principal executive offices are located in Dublin, Ireland.
Why It Matters
This filing provides investors with updated financial information for ICON PLC, crucial for assessing the company's performance and financial health during the first quarter of 2024.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) providing standard disclosures and financial data, not indicating any unusual risks.
Key Numbers
- 20240331 — Period End Date (The report covers financial data up to this date.)
- 2023-12-31 — Prior Year End Date (Financial data as of this date is included for comparison.)
Key Players & Entities
- ICON PLC (company) — Filer of the report
- 0001060955 (company) — Central Index Key for ICON PLC
- Dublin (location) — Location of ICON PLC's business and mailing address
FAQ
What is the filing type and period of report for ICON PLC?
The filing type is a 6-K, and the period of report is March 31, 2024.
Where are ICON PLC's principal executive offices located?
ICON PLC's principal executive offices are located at South County Business Park, Leopardstown, Dublin 18, Ireland.
What specific financial items are mentioned for December 31, 2023?
The filing mentions Common Stock, Additional Paid-In Capital, Other Undenominated Capital, Accumulated Other Comprehensive Income, and Retained Earnings as of December 31, 2023.
What is the SIC code for ICON PLC?
The Standard Industrial Classification (SIC) code for ICON PLC is 8731, which falls under Services-Commercial Physical & Biological Research.
What is the filing date of this 6-K report?
This 6-K report was filed on April 25, 2024.
Filing Stats: 4,566 words · 18 min read · ~15 pages · Grade level 16.3 · Accepted 2024-04-25 16:32:00
Key Financial Figures
- $5,515 million — senior secured term loan facility of US$5,515 million and a senior secured revolving credit f
- $300 million — ity in an initial aggregate amount of US$300 million (subsequently increased on May 2, 2023
- $500 million — sequently increased on May 2, 2023 to US$500 million). On March 14, 2024, the parties to t
- $275.0 million — g mandatory and voluntary repayments of $275.0 million of the senior secured term loan facilit
- $2.0 million — ted with previously capitalized fees of $2.0 million. In addition, the Company drew down $
- $50.0 million — n. In addition, the Company drew down $50.0 million of the senior secured revolving loan fa
- $55.0 million — ured revolving loan facility and repaid $55.0 million. Refer to note 10. Bank credit lines an
Filing Documents
- iclr-20240331.htm (6-K) — 940KB
- ex991icon-amendmentno3.htm (EX-99.1) — 1742KB
- 0001060955-24-000028.txt ( ) — 8573KB
- iclr-20240331.xsd (EX-101.SCH) — 52KB
- iclr-20240331_cal.xml (EX-101.CAL) — 73KB
- iclr-20240331_def.xml (EX-101.DEF) — 267KB
- iclr-20240331_lab.xml (EX-101.LAB) — 534KB
- iclr-20240331_pre.xml (EX-101.PRE) — 435KB
- iclr-20240331_htm.xml (XML) — 933KB
Business
Business ICON is a contract research organization ("CRO"), providing outsourced services on a global basis to pharmaceutical, biotechnology, medical device and government and public health organizations. We specialize in the strategic development, management and analysis of programs that support all stages of the clinical development process - from compound selection to Phase I-IV clinical studies. Our vision is to be the healthcare intelligence partner of choice by delivering industry leading solutions and best in class performance in clinical development. We believe that we are one of a select group of CROs with the expertise and capability to conduct clinical trials in the major therapeutic areas on a global basis and have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated "full service" solution. At March 31, 2024 we had approximately 41,150 employees in 102 locations in 54 countries. During the three months ended March 31, 2024, we derived 38.7%, 49.9% and 11.4% of our revenue in the United States, Europe and Rest of World, respectively (during the period ended March 31, 2023: 42.7%, 46.8% and 10.5%, respectively). We began operations in 1990 and have expanded our business through organic growth, together with a number of strategic acquisitions to enhance our capabilities and expertise in certain areas of the clinical development process. We are incorporated in Ireland and our principal executive office is located at: South County Business Park, Leopardstown, Dublin 18, D18 X5R3, Republic of Ireland. The contact telephone number of this office is +353-1-291-2000. Recent developments Repricing - senior secured term loan facility and senior secured revolving credit facility On July 1, 2021, and in connection with the PRA merger, ICON plc and certain subsidiaries entered into a credit agreement (the "Credit Agreement") which provided for a senior secured term loan facility of US$5,515 million